Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.

Also called NCT06812546

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06812546
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06812546. Randomized; single masking; primary purpose treatment. Start 2025-04-01 (anticipated); primary completion 2026-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction
Acronym
VIC-MI
Condition
Heart Failure
Condition
Acute Myocardial Infarction (AMI)
Condition
Acute Heart Failure (AHF)
Intervention (Drug)
Vericiguat
Lead sponsor
Dongying Zhang (class: other)
Collaborator
The Second Affiliated Hospital of Chongqing Medical University (class: other)
Collaborator
First Affiliated Hospital of Chongqing Medical University (class: other)

Record details

Record id
cardio:ct-nct06812546
Content hash
8f02d5cf8659ceaa3ad444f323ebed4178b7264e10b4e5821975638d00fd5df9